News
Displaying 161–170 of 508
-
Foundation News
Commitment to expand translational research acceleration program and fund career development award.
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Foundation NewsNoteworthy Foundation executive increases role within organization.
-
Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
In the PressInvestment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
In the Press
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
-
In the Press
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
-
Organizations collaborate on inherited macular dystrophy program
In the PressThe Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
.png)
